Gilead Sciences (GILD)
(Delayed Data from NSDQ)
$83.61 USD
+0.57 (0.69%)
Updated Sep 27, 2024 04:00 PM ET
After-Market: $83.61 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$83.61 USD
+0.57 (0.69%)
Updated Sep 27, 2024 04:00 PM ET
After-Market: $83.61 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth A Momentum A VGM
Zacks News
Gilead's (GILD) Veklury Gets EC Nod for Use in Early COVID-19
by Zacks Equity Research
Gilead's (GILD) Veklury can now be used in the EU at the early stages of COVID-19 to help prevent disease progression in high-risk patients.
Vir (VIR), Glaxo's Xevudy Wins EC Approval for COVID-19
by Zacks Equity Research
Vir Biotechnology, Inc. (VIR) and partner GlaxoSmithKline obtain the European Commission's nod for Xevudy for the early treatment of COVID-19.
Gilead Sciences (GILD) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Gilead Sciences (GILD) closed the most recent trading day at $72.31, moving +1.54% from the previous trading session.
Merck's (MRK) HIV Studies on Islatravir Put on Clinical Hold
by Zacks Equity Research
With the FDA's clinical hold, no new studies can be initiated on Merck's (MRK) islatravir. While six studies on islatravir have been placed on full clinical hold, seven have been put on partial clinical hold.
Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Gilead Sciences (GILD) closed the most recent trading day at $70.25, moving -0.07% from the previous trading session.
Merck (MRK) Pauses Enrolment in HIV-1 Prevention Studies
by Zacks Equity Research
Merck (MRK) pauses enrolment for two phase III studies evaluating islatravir for pre-exposure prophylaxis of HIV-1 infection, following the recommendation of an external data monitoring committee.
Amazon's (AMZN) AWS Gets Selected by Gilead, Boosts Clientele
by Zacks Equity Research
Amazon's (AMZN) AWS is chosen by Gilead Sciences as the preferred cloud provider.
The Zacks Analyst Blog Highlights: Accenture, Raytheon, Becton, Dickinson and Co, Boeing and Gilead Sciences
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Accenture, Raytheon, Becton, Dickinson and Co, Boeing and Gilead Sciences
Top Analyst Reports for Accenture, Raytheon & Becton, Dickinson
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Accenture plc (ACN), Raytheon Technologies Corporation (RTX), and Becton, Dickinson, and Company (BDX).
Ligand's (LGND) Drug-Developing Technologies Holds Potential
by Zacks Equity Research
Ligand's (LGND) Captisol technology is a key driver for its topline. The company plans to spin off another potential technology platform, OmniAb, into a separate company.
Gilead Sciences (GILD) Stock Gains 20% YTD: What Lies Ahead?
by Zacks Equity Research
Gilead's (GILD) performance in the year has been pretty good on contribution from Veklury. The company is now focusing on its oncology business as the virology business faces challenges.
Biotech Stock Roundup: Drug Approvals for BMRN, Updates From BIIB, BMY, MRNA & More
by Zacks Equity Research
Drug approvals for BioMarin (BMRN) and regulatory updates from Biogen (BIIB), among others, have been the biotech sector's few key highlights during the past week.
Gilead (GILD) Gets EU Nod for Breast Cancer Drug, Trodelvy
by Zacks Equity Research
The European Commission grants marketing authorization to Gilead's (GILD) Trodelvy as a monotherapy for the second-line treatment of adults with metastatic triple-negative breast cancer.
Gilead (GILD) Files BLA for Bulevirtide for Hepatitis Delta Virus
by Zacks Equity Research
Gilead (GILD) submits a biologics license application to the FDA for bulevirtide for the treatment of chronic hepatitis delta virus infection in adults with compensated liver disease.
Gilead (GILD) Exercises Options to Three Arcus Programs
by Zacks Equity Research
Gilead (GILD) exercises options to Arcus' anti-TIGIT Program (domvanalimab and AB308), etrumadenant (A2a/A2b Adenosine Receptor Antagonist), and quemliclustat (small Molecule CD73 Inhibitor).
Gilead (GILD), Everest Medicine Report Phase II Cancer Study Data (Revised)
by Zacks Equity Research
Gilead (GLD) and partner Everest Medicine report that the mid-stage study of sacituzumab govitecan for triple-negative breast cancer achieved its main goal.
Gilead (GILD), Everest Medicine Report Phase II Cancer Study Data
by Zacks Equity Research
Gilead (GLD) and partner Everest Medicine report that the mid-stage study of sacituzumab govitecan for triple-negative breast cancer achieved its main goal.
Ligand (LGND) Beats on Q3 Earnings, Plans to Separate OmniAb
by Zacks Equity Research
Ligand (LGND) reports encouraging third-quarter 2021 numbers by beating estimates on both counts.
How Are Biotech ETFs Reacting to These Q3 Earnings Releases?
by Sweta Jaiswal, FRM
Let's take a look at some big biotechnological earnings releases to see if these will impact ETFs exposed to the space.
FATE's Q3 Loss Narrower Than Expected, Pipeline in Focus
by Zacks Equity Research
FATE reports a year-over-year wider loss on increased R&D expenses in the third quarter.
Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for IBB
Intercept (ICPT) Beats on Q3 Earnings & Sales, Ups View
by Zacks Equity Research
Intercept (ICPT) posts a narrower loss in the third quarter and sales beat estimates.
Gilead (GILD) Q3 Earnings Beat on Increased Veklury Sales
by Zacks Equity Research
Gilead (GILD) beats on sales and earnings in the third quarter. While the HIV business is affected by the pandemic and generics, Veklury maintains momentum.
Markets Close at or Near Record Highs; Sales Misses for AAPL, AMZN, SBUX
by Mark Vickery
Most of these economic metrics and earnings reports are a peek in the rearview mirror; the real news is ahead of us.
Gilead Sciences (GILD) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Gilead (GILD) delivered earnings and revenue surprises of 54.07% and 19.16%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?